News & Updates

In the treatment of patients with uncontrolled type 2 diabetes (T2D), adding empagliflozin to the combination of metformin plus evogliptin improves glycaemic control and other metabolic outcomes, as shown in a phase III study conducted in South Korea.

In patients with mild autonomous cortisol secretion (MACS), overnight metyrapone therapy helps to partially retore hypothalamic-pituitary-adrenal (HPA) axis balance and improve sleep and mood, with a favourable tolerability profile, according to a phase II trial.

Researchers from the Chinese University of Hong Kong (CUHK) have developed a novel molecule, BB56, which can potentially serve as a lead compound for the development of new drugs for neuroinflammatory disorders.

Subcutaneous injections of olatorepatide, an investigational dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, are associated with up to a 19-percent decrease in body weight and favourable gastrointestinal (GI) tolerability in Chinese adults with overweight or obesity, as shown in the phase III LIGHTEN study.

Treatment with lebrikizumab maintains improvements in skin and itch over 5 years in adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to the ADlong long-term extension trial presented at EADV 2026.

Tambotatug pelitecan (Tam-Peli), a novel B7-H3–targeting antibody–drug conjugate, delivers significant survival boost in relapsed small-cell lung cancer (SCLC) as compared with topotecan, according to the phase III TAISHAN-302 trial.

Microbiome-derived deoxycholic acid (DCA) worsens portal hypertension by boosting TPH1-dependent 5-hydroxytryptamine (5-HT) biosynthesis, which activates portal vein smooth muscle cell contraction via HTR1A-GIRK3 signalling, a study has found.